Skip to main content
K

KOMIPHARM INTERNATIONAL CO., LTD. — Investor Relations & Filings

Ticker · 041960 ISIN · KR7041960006 KO Manufacturing
Open in API
Filings indexed 325 across all filing types
Latest filing 2026-04-08 Regulatory Filings
Country KR South Korea
Listing KO 041960

About KOMIPHARM INTERNATIONAL CO., LTD.

https://komipharm.co.kr/en/

Komipharm International Co., Ltd. is a biopharmaceutical company engaged in the development, manufacturing, and sale of products for both animal and human health. Its Animal Health Division provides a portfolio of veterinary vaccines, pharmaceuticals, and disinfectants. The company's Pharmaceutical Division is dedicated to the research and development of novel therapeutic agents, with key research areas including anticancer drugs and treatments for cancer-related pain and autoimmune diseases. Leveraging extensive experience, the company focuses on intensive R&D to expand its presence in the global bio-industry.

Recent filings

Filing Released Lang Actions
[기재정정]단일판매ㆍ공급계약체결
Regulatory Filings Classification · 1% confidence The document is a corporate disclosure (“공시”) announcing the details and a correction of a single sales & supply contract with a government procurement agency. It is neither a financial report (10-K/IR), earnings release, management or board change notice, share transaction nor any of the other specific report types. Therefore, it falls under the fallback category of general regulatory announcements.
2026-04-08 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled “정기주주총회결과” (Annual General Meeting Results) and details the resolutions passed, vote counts, percentages for each agenda item, and related financial statement approvals. It is not a presentation or the full annual report but specifically the official results of the AGM votes. This aligns precisely with Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2026-03-26 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 1% confidence The document is a corporate disclosure titled “주식매수선택권 부여에 관한 신고,” detailing the grant of stock options by the company to its directors and employees. This involves potential issuance of new shares under the option plan and adjustments to capital structure. Under our taxonomy, this falls under “Share Issue/Capital Change” rather than insider trades (DIRS) or a general regulatory announcement (RNS). Therefore, the correct classification is SHA.
2026-03-26 Korean
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a formal regulatory filing from the Korea Exchange (KRX) system titled '감사보고서 제출' (Submission of Audit Report). It provides the audit opinion, key financial data (assets, liabilities, equity, profit/loss), and details regarding the auditor (Samjong Accounting Corp) for the fiscal year ending 2025-12-31. While it contains financial data, it is a standard regulatory disclosure of the audit results rather than the full 10-K annual report document itself. In the context of Korean regulatory filings (DART/KIND), this is classified as a regulatory filing regarding the submission of audit results. FY 2025
2026-03-18 Korean
사업보고서 (2025.12)
Annual Report Classification · 1% confidence The document is a 'Business Report' (사업보고서) for the 54th fiscal year (2025) of Komipharm. It contains comprehensive financial statements, management discussion and analysis, corporate governance details, and operational information. This is the standard Korean regulatory filing equivalent to an Annual Report (10-K). FY 2025
2026-03-18 Korean
[기재정정]주주총회소집결의
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal regulatory filing from Kormipharm regarding the 'Resolution to Convene a General Meeting of Shareholders' (주주총회소집결의). It details the date, location, and specific agenda items for the upcoming Annual General Meeting (AGM), including a correction notice (정정신고) for an added agenda item. Since this document provides the official notice and agenda for the shareholder meeting, it falls under the category of Proxy Solicitation & Information Statement (PSI), as it informs shareholders of the meeting details and the matters to be voted upon.
2026-03-11 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.